SCHEMBL20504600

SCHEMBL20504600

CCOC(=O)c1c(O)c2cc(OC)c(OCCCN3CCCC3)cc2[nH]c1=O

nearest known ligand 0.64

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 5/20 0.64
▸ ALDH1A1 P00352 4/20 0.64
▸ HSD17B10 Q99714 3/20 0.64
▸ ALOX15 P16050 1/20 0.64
▸ KMT2A Q03164 1/20 0.64
▸ LMNA P02545 1/20 0.55
▸ RAD52 P43351 1/20 0.55
▸ SPIN1 Q9Y657 1/20 0.47
▸ CACNA1F O60840 3/20 0.47
▸ CACNA1D Q01668 3/20 0.47
▸ CACNA1S Q13698 3/20 0.47
▸ CACNA1C Q13936 3/20 0.47
▸ HRH3 Q9Y5N1 1/20 0.46
▸ ACHE P22303 2/20 0.45
▸ HPGD P15428 1/20 0.45
▸ MAPK1 P28482 1/20 0.45
▸ L3MBTL1 Q9Y468 1/20 0.45
▸ MAPT P10636 1/20 0.45
▸ BCHE P06276 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11383772 0.85 KDM4E (0.57) KDM4EALDH1A1HSD17B10ALOX15KMT2A
SCHEMBL19477129 0.80 SPIN1 (0.54) KDM4EALDH1A1HSD17B10ALOX15KMT2A
SCHEMBL30474838 0.78 KDM4E (0.60) KDM4EALDH1A1HSD17B10ALOX15KMT2A
SCHEMBL6344529 0.76 EHMT2 (0.52) SPIN1
SCHEMBL23784378 0.75 EHMT2 (0.51) KDM4EALDH1A1HSD17B10ALOX15KMT2A
SCHEMBL20504510 0.75 EHMT2 (0.52) SPIN1
SCHEMBL11816205 0.75 KDM5A (0.47) KDM4EALDH1A1HSD17B10ALOX15KMT2A
SCHEMBL23784367 0.74 EHMT2 (0.52) KDM4EALDH1A1HSD17B10ALOX15KMT2A
Formic Acid SCHEMBL20580538 0.73 KDM4E (0.49) KDM4EALDH1A1HSD17B10ALOX15KMT2A
SCHEMBL20304023 0.73 EHMT2 (0.56) KDM4EALDH1A1HSD17B10ALOX15KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10407423-B2 Compounds as inhibitors of DNA methyltransferases FUNDACIÓN PARA LA INVESTIGACIÓN MÉDICA APLICADA (ES) 2019-09-10 — — US disclosed
US-20180362525-A1 NOVEL COMPOUNDS AS INHIBITORS OF DNA METHYLTRANSFERASES FUNDACIÓN PARA LA INVESTIGACIÓN MÉDICA APLICADA (ES) 2018-12-20 — — US disclosed
EP-3377490-A1 NOVEL COMPOUNDS AS INHIBITORS OF DNA METHYLTRANSFERASES Fundacion para la Investigacion Medica Aplicada (ES) 2018-09-26 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180362525-A1 NOVEL COMPOUNDS AS INHIBITORS OF DNA METHYLTRANSFERASES DNMT3B, DNMT3A, DNMT1 KDM4E 61/4885ALDH1A1 323/4885HSD17B10 2122/4885
US-10407423-B2 Compounds as inhibitors of DNA methyltransferases DNMT3B, DNMT3A, DNMT1 KDM4E 64/4885ALDH1A1 367/4885HSD17B10 2175/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback